What captured your attention on DRUGDOCS® in July?
1️⃣ Yeztugo® for chronic myeloid leukemia
2️⃣ Yorvipath® to slash LDL-C via PCSK9 inhibition
3️⃣ Lynozyfic® GLP-1 agonist for type 2 diabetes

🔍 All the data, all the studies, right here: drugdocs.com
#Yeztugo #Yorvipath #Lynozyfic

Linvoseltamab (Lynozyfic) 2025 Updates: Uses in Cancer, Dosage, Side Effects, Expectations, and More - OncoDaily Linvoseltamab (Lynozyfic) is anti CD38 mab, which used for relapsed or refractory multiple myeloma. learn about its uses, dose, side effects.

Linvoseltamab (Lynozyfic) 2025 Updates: Uses in Cancer, Dosage, Side Effects, Expectations, and More

oncodaily.com/drugs/linvos...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Linvoseltamab #Lynozyfic #MM #RRMM #Myeloma

Regeneron Pharmaceuticals, kan kanseri multipl miyelomlu bazı hastalar için #Lynozyfic tedavisinin Gıda ve İlaç Dairesi tarafından hızlandırılmış onayını aldı.

📍 #Lynozyfic approuvé dans l' #UE pour le traitement du #MyélomeMultiple R/R

www.ema.europa.eu/fr/documents...